Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 10, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and transactions involving the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transactions and director disclosures rather than financial performance metrics.
Material Changes
The filing details specific share movements during early September 2003:
- Employee Benefit Trust Sales: The Trust sold 312 ordinary shares on September 5, 2003, at £12.57 per share, and 9 ordinary shares on September 8, 2003, at £12.59 per share.
- Trust Transfers: On September 9, 2003, 912 ordinary shares were transferred from the Trust to a participant in the Annual Investment Plan.
- Director Acquisition: Director Mr. J.D. Coombe acquired 20 ordinary shares on September 9, 2003, at £12.54 per share through the ShareReward Plan (10 shares via personal contribution and 10 via company matching).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure regarding equity ownership changes.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following the reported sales and transfers.
- Confirm the aggregate shareholding of Director Mr. J.D. Coombe post-acquisition.
- Review the terms of the ShareReward Plan to understand the matching contribution structure.
- Check subsequent filings for any further changes in director interests or trust activities.